Update on tubulin-binding agents

被引：133
作者：
Attard, G
Greystoke, A
Kaye, S
De Bono, J
机构：
[1] Inst Canc Res, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England
来源：
PATHOLOGIE BIOLOGIE | 2006年 / 54卷 / 02期
关键词：
tubulin-binding; taxanes; vinca alkaloids; dolastations; vinflunine; combretastatin analogues;
D O I：
10.1016/j.patbio.2005.03.003
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. (C) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码：72 / 84
页数：13
相关论文
共 127 条
[91]  
Roberge M, 2000, CANCER RES, V60, P5052
[92]   Microtubule treadmilling in vivo [J].
Rodionov, VI ;
Borisy, GG .
SCIENCE, 1997, 275 (5297) :215-218
[93]   EPO906 (Epothilone B): A promising novel microtubule stabilizer [J].
Rothermel, J ;
Wartmann, M ;
Chen, TL ;
Hohneker, J .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :51-55
[94]  
Rowinsky EK, 2002, CLIN CANCER RES, V8, P2759
[95]  
RUBIN EH, 2001, PHASE 1 PHARM TRIAL
[96]   Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results [J].
Rustin, GJS ;
Galbraith, SM ;
Anderson, H ;
Stratford, M ;
Folkes, LK ;
Sena, L ;
Gumbrell, L ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2815-2822
[97]   Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer [J].
Saad, ED ;
Kraut, EH ;
Hoff, PM ;
Moore, DF ;
Jones, D ;
Pazdur, R ;
Abbruzzese, JL .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05) :451-453
[98]   Antitumor activity of a kinesin inhibitor [J].
Sakowicz, R ;
Finer, JT ;
Beraud, C ;
Crompton, A ;
Lewis, E ;
Fritsch, A ;
Lee, Y ;
Mak, J ;
Moody, R ;
Turincio, R ;
Chabala, JC ;
Gonzales, P ;
Roth, S ;
Weitman, S ;
Wood, KW .
CANCER RESEARCH, 2004, 64 (09) :3276-3280
[99]  
SCHOFFSKI P, 2003, P AN M AM SOC CLIN, V22, P211
[100]   Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule [J].
Sessa, C ;
Weigang-Köhler, K ;
Pagani, O ;
Greim, G ;
Mora, O ;
De Pas, T ;
Burgess, M ;
Weimer, I ;
Johnson, R .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (18) :2388-2396
45678910111213